Development and validation of PBPK models for genistein and daidzein for use in a next-generation risk assessment.

ABSTRACT:

Introduction

All cosmetic ingredients must be evaluated for their safety to consumers. In the absence of in vivo data, systemic concentrations of ingredients can be predicted using Physiologically based Pharmacokinetic (PBPK) models. However, more examples are needed to demonstrate how they can be validated and applied in Next-Generation Risk Assessments (NGRA) of cosmetic ingredients. We used a bottom-up approach to develop human PBPK models for genistein and daidzein for a read-across NGRA, whereby genistein was the source chemical for the target chemical, daidzein.

Methods

An oral rat PBPK model for genistein was built using PK-Sim^® and in vitro ADME input data. This formed the basis of the daidzein oral rat PBPK model, for which chemical-specific

SUBMITTER: Najjar A 

PROVIDER: S-EPMC11483610 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature